Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call

Phase 2mosliciguatNeutral

AI Analysis

Summary

Roivant will present topline results from the Phase 2 PHocus study of mosliciguat for pulmonary hypertension associated with interstitial lung disease at the ERS Congress 2026 on September 8, 2026, followed by an investor call.

Clinical Trial Data

Phase

Phase 2

Importance:6/10

Sentiment:

0.00

Phase 2 datapulmonary hypertensioninterstitial lung diseaseconference presentationinvestor call

Related Companies

$ROIV

Read the original article

Published by GlobeNewswire Pharma on September 6, 2026 5:00 AM

Read Original